In the current study, we found that FT@XBP1 treatment could not only significantly inhibit liver lipid accumulation and collagen deposition in the FFC diet fed mice but also improve high-fat-induced intestinal barrier dysfunction, as demonstrated by the restoration the integrity of the intestinal barrier (Figure 6A) and increased levels of ZO-1 protein expression (Figure 6B), which partially restored intestinal flora structure, reduced endotoxemia and alleviated liver inflammation. Here, XBP1 is linked to serum lipopolysaccharide activity.